- The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region.
- Renuvion is a proprietary helium plasma and radiofrequency technology.
- Related: Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin.
- This clearance offers a new option for physicians and patients to improve loose skin on the neck and submental region.
- With this clearance, Renuvion is the only product that is FDA-cleared to improve the appearance of loose skin on the neck and chin.
- Renuvion provides a minimally-invasive and cost-effective option with minimal downtime. The results reveal a more contoured and smoother neck and jawline.
- Price Action: APYX shares are up 9.20% at $8.31 during the market session on the last check Monday
Ring Energy Q2 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $85.00M Beat $66.46M Estimate
Ring Energy (AMEX:REI) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.23 by 26.09 percent. This is a 314.29 percent increase over earnings of $0.07 per share from the same
